{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:11:57Z","timestamp":1792044717401,"version":"4.4.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>With the increasing clinical use of tirzepatide, its safety profile has garnered significant attention. This article systematically reviews case reports of tirzepatide-associated adverse drug reactions (ADRs) to summarize their characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We searched PubMed, Web of Science, ScienceDirect, Wiley Online, and Embase databases for case reports on tirzepatide adverse events using the keywords: \u201ctirzepatide\u201d, \u201cadverse reaction\u201d, \u201cadverse event\u201d, \u201cside effect\u201d, \u201csafety\u201d, \u201ccase report\u201d, \u201cinduced\u201d, \u201cassociated\u201d, and \u201crelated\u201d. Statistical analysis was performed on the identified cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 43 cases of tirzepatide ADR were identified from 37 articles. Among these patients (24 female, 19 male; mean age 50.23 \u00b1 17.24\u00a0years), 19 involved concomitant medications affecting multiple systems. ADR was reported in each dosage of tirzepatide, with the most occurring at 2.5\u20135\u00a0mg (16 cases), and primarily occurred within 1\u20136\u00a0months of initiation. Regarding rechallenge, 15 patients discontinued tirzepatide, three continued use, and one reduced the dose. ADR involved seven gastrointestinal tract and endocrine systems, including liver and gallbladder, circulation, nerve, skin, and urinary. Notable manifestations included ketoacidosis, liver injury, hypotension, intestinal obstruction, and allergic reactions. Among them, ketoacidosis and common peroneal neuropathy causing foot sagging, acute appendicitis, lower limb venous thrombosis, gastric outlet obstruction, gastric emptying delay, and acute liver injury were not mentioned in the drug instructions. ADR correlation assessment was performed for 8 patients:4 cases of cardiovascular events and ketoacidosis were all evaluated as \u201cprobable\u201d using the Naranjo scale, 3 cases of liver injury were assessed by RUCAM (2 case as \u201cpossible\u201d, 1 cases as \u201cprobable\u201d), 1 case did not specify the evaluation method, with the result being \u201chighly probable\u201d. All 43 patients underwent ADR correlation re-evaluation:32 cases (74.42%) were assessed as \u201cprobable\u201d,11 cases (25.58%) were assessed as \u201cpossible\u201d.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tirzepatide-associated ADRs most commonly occur within the first 6 months of treatment, primarily affecting the digestive, endocrine, liver, and gallbladder systems. Enhanced monitoring of liver and kidney function is warranted, especially in patients concurrently taking other potentially hepatotoxic or nephrotoxic medications. Additionally, intensified therapeutic drug monitoring is recommended for patients with cardiovascular disease, those requiring weight-based dosing adjustments, and those experiencing rapid weight loss.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1608657","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:29:41Z","timestamp":1751347781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengmeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"004813","DOI":"10.12890\/2024_004813","article-title":"Tirzepatide-related acute liver injury","volume":"11","author":"Abdullah","year":"2024","journal-title":"Eur. J. Case Rep. Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e45261","DOI":"10.7759\/cureus.45261","article-title":"An incidental finding of a glucagon-like peptide 1 (GLP-1)-Induced acute kidney injury: a case report","volume":"15","author":"Aleman","year":"2023","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e01551","DOI":"10.14309\/crj.0000000000001551","article-title":"Tirzepatide-associated colonic ischemia","volume":"11","author":"Bayless","year":"2024","journal-title":"ACG Case Rep. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.eprac.2024.03.168","article-title":"#1677365 A case of a 58-year-old man with type 2 DM who was diagnosed with pancreatic adenocarcinoma after treatment with tirzepatide","volume":"30","author":"Betchvaia","year":"2024","journal-title":"Endocr. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e946133","DOI":"10.12659\/AJCR.946133","article-title":"Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit?","volume":"25","author":"Bitar","year":"2024","journal-title":"Am. J. Case Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102316","DOI":"10.1016\/j.cdnut.2024.102316","article-title":"A case of compounded tirzepatide-induced psychiatric adverse effects","volume":"8","author":"Bobbs","year":"2024","journal-title":"Curr. Dev. Nutr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.nutr.26.061505.111258","article-title":"Fuel metabolism in starvation","volume":"26","author":"Cahill","year":"2006","journal-title":"Annu. Rev. Nutr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J. Endocrinol. Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/DMSO.S496739","article-title":"Appendicitis after initiation of tirzepatide","volume":"18","author":"Chan","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"Jama"},{"key":"B11","first-page":"580","article-title":"\u201cSlimmer's paralysis\u201d: peroneal neuropathy in anorexia nervosa","volume":"65","author":"Denys","year":"2023","journal-title":"Tijdschr Psychiatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"B13","article-title":"Drug interaction results between tirzepatide and sacubitril\/valsatan M C, Spironolaction, empaglilozin, or dapagliflozin. in micromedex: drug interaction (columbia basin college lairery ed.)","year":"2023"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S3152","DOI":"10.14309\/01.ajg.0001049408.79846.f0","article-title":"S5010 A challenging case of gastric bezoar in a patient on tirzepatide","volume":"119","author":"Fadel","year":"2024","journal-title":"Official J. Am. Coll. Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.aace.2024.08.011","article-title":"Extensive deep vein thrombosis in a young man taking tirzepatide for weight loss","volume":"10","author":"Farooqi","year":"2024","journal-title":"AACE Clin. Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jdcr.2025.02.018","article-title":"Tirzepatide-induced Lichen planus pigmentosus","volume":"59","author":"Fisher","year":"2025","journal-title":"JAAD Case Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1016\/j.cgh.2024.06.025","article-title":"First report of tirzepatide hepatotoxicity with jaundice","volume":"22","author":"Fontana","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.eprac.2023.03.034","article-title":"Abstract #1402779: a case of possible tirzepatide-induced pancreatitis","volume":"29","author":"Gomez Casanovas","year":"2023","journal-title":"Endocr. Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"A2334","DOI":"10.1016\/j.chest.2023.07.1569","article-title":"A rare case of a large bowel obstruction due to tirzepatide","volume":"164","author":"Gordon","year":"2023","journal-title":"CHEST"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.eprac.2024.03.258","article-title":"#1698670 A case of fatal fulminant necrotizing pancreatitis in a patient with recent tirzepatide initiation","volume":"30","author":"Grennan","year":"2024","journal-title":"Endocr. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"A401","DOI":"10.1210\/jendso\/bvae163.765","article-title":"6660 euglycemic DKA induced by SGLT-2 inhibitor following administration ofTirzepatide","volume":"8","author":"Gurel","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e50112","DOI":"10.7759\/cureus.50112","article-title":"Tirzepatide-induced biphasic anaphylactic reaction: a case report","volume":"15","author":"He","year":"2023","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0168878","DOI":"10.1371\/journal.pone.0168878","article-title":"Weight change and risk of venous thromboembolism: the troms\u00f8 study","volume":"11","author":"Horvei","year":"2016","journal-title":"PLOS ONE"},{"key":"B27","doi-asserted-by":"publisher","first-page":"004357","DOI":"10.12890\/2024_004357","article-title":"Tirzepatide-induced ketoacidosis in non-diabetic patients","volume":"11","author":"Iqbal","year":"2024","journal-title":"Eur. J. Case Rep. Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e78090","DOI":"10.7759\/cureus.78090","article-title":"Acute functional gastric outlet obstruction associated with low-dose tirzepatide","volume":"17","author":"Iskander","year":"2025","journal-title":"Cureus"},{"key":"B29","first-page":"21","article-title":"Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with Migraines and Hypoglycemia: A Case Report","volume":"23","author":"Jamail","year":"2024","journal-title":"Integr Med (Encinitas)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1001\/jamainternmed.2024.2919","article-title":"Tirzepatide-induced rapid weight loss-related thyrotoxicosis","volume":"184","author":"Karakus","year":"2024","journal-title":"JAMA Intern Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.japh.2023.09.011","article-title":"Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy","volume":"64","author":"Kido","year":"2024","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e01544","DOI":"10.14309\/crj.0000000000001544","article-title":"Dramatic changes in thiopurine metabolite levels in a patient with inflammatory bowel disease treated with tirzepatide for weight loss","volume":"11","author":"Klein","year":"2024","journal-title":"ACG Case Rep. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1412A","DOI":"10.1002\/hep.32218","article-title":"A selective GR modulator, induced a rapid and significant reduction in liver fat content in a randomized, placebocontrolled phase 2a study in patients with non-alcoholic steato-hepatitis","volume":"74","author":"Kowdley","year":"2021","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.soard.2020.06.054","article-title":"The results of surgical decompression in the treatment of foot drop due to peroneal nerve entrapment after bariatric surgery","volume":"16","author":"Lale","year":"2020","journal-title":"Surg. Obes. Relat. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e51460","DOI":"10.7759\/cureus.51460","article-title":"A case report of systemic allergic reaction to the dual glucose-dependent insulinotropic Polypeptide\/glucagon-like Peptide-1 receptor agonist tirzepatide","volume":"16","author":"Le","year":"2024","journal-title":"Cureus"},{"key":"B37","doi-asserted-by":"publisher","first-page":"luaf028","DOI":"10.1210\/jcemcr\/luaf028","article-title":"Euglycemic ketoacidosis following coadministration of an SGLT2 inhibitor and tirzepatide","volume":"3","author":"Louwagie","year":"2025","journal-title":"JCEM Case Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e76007","DOI":"10.7759\/cureus.76007","article-title":"Acute pancreatitis caused by tirzepatide","volume":"16","author":"Mando","year":"2024","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.862","article-title":"FRI643 tirzepatide associated partial small bowel obstruction: a case report","volume":"7","author":"Mathew","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the world health organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"Mcintyre","year":"2025","journal-title":"J. Affect Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/15563650.2023.2233835","article-title":"Tirzepatide-induced starvation ketoacidosis: a case report","volume":"61","author":"Mercer","year":"","journal-title":"Clin. Toxicol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/15563650.2023.2277337","article-title":"Tirzepatide-associated starvation ketoacidosis","volume":"61","author":"Mercer","year":"","journal-title":"Clin. Toxicol. (Phila)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e45181","DOI":"10.7759\/cureus.45181","article-title":"Tirzepatide-induced injection site reaction","volume":"15","author":"Mizumoto","year":"2023","journal-title":"Cureus"},{"key":"B45","first-page":"562","article-title":"Case Report: Small Bowel Obstruction After Starting Tirzepatide (Mounjaro)","volume":"110","author":"Morgenthaler","year":"2024","journal-title":"Am Fam Physician."},{"key":"B46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.gie.2024.04.2900","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients","volume":"100","author":"Nadeem","year":"2024","journal-title":"Gastrointest. Endosc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"S2486","DOI":"10.14309\/01.ajg.0000965224.61011.89","article-title":"S3896 the risks of the new weight loss medications","volume":"118","author":"Peicher","year":"2023","journal-title":"Official J. Am. Coll. Gastroenterology | ACG"},{"key":"B48","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa","year":"2025"},{"key":"B49","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/asheducation-2005.1.458","article-title":"Acquired risk factors for venous thromboembolism in medical patients","volume":"2005","author":"Prandoni","year":"2005","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.128","article-title":"SAT680 mounjaro: a side effect","volume":"7","author":"Rao","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"B51","doi-asserted-by":"publisher","first-page":"17-0081","DOI":"10.1530\/EDM-17-0081","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla","year":"2017","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s13181-023-00930-w","article-title":"Valproic Acid Toxicity After Initiation of Injectable Weight-Loss Drug: A Case Report","volume":"19","author":"Rivera","year":"2023","journal-title":"Journal of Medical Toxicology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/obr.12199","article-title":"Metabolically healthy and unhealthy obese-the 2013 stock conference report","volume":"15","author":"Samocha-Bonet","year":"2014","journal-title":"Obes. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e2423385","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from world health organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B56","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s11695-019-04285-6","article-title":"Neurological complication after laparoscopic sleeve gastrectomy: foot drop","volume":"30","author":"\u015een","year":"2020","journal-title":"Obes. Surg."},{"key":"B57","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1159\/000518377","article-title":"Varied presentation and importance of MR neurography of the common fibular nerve in slimmer's paralysis","volume":"13","author":"Shields","year":"2021","journal-title":"Case Rep. Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5811\/cpcem.2020.2.44736","article-title":"Diet-induced ketoacidosis in a non-diabetic: a case report","volume":"4","author":"Slade","year":"2020","journal-title":"Clin. Pract. Cases Emerg. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e01484","DOI":"10.14309\/crj.0000000000001484","article-title":"A rare case of tirzepatide-induced hepatotoxicity","volume":"11","author":"Sohal","year":"2024","journal-title":"ACG Case Rep. J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"B61","doi-asserted-by":"publisher","first-page":"574","DOI":"10.15403\/jgld-5967","article-title":"Idiosyncratic acute liver failure induced by tirzepatide","volume":"33","author":"Terrington","year":"2024","journal-title":"J. Gastrointestin Liver Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"23247096241264635","DOI":"10.1177\/23247096241264635","article-title":"The tirzepatide drop: beware of slimmer's paralysis","volume":"12","author":"Tucker","year":"2024","journal-title":"J. Investig. Med. High. Impact Case Rep."},{"key":"B63","article-title":"Ozempic (Semaglutide). Safety-related labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)","year":"2023"},{"key":"B16","article-title":"FDA Approves First Medication for Obstructive Sleep Apnea","year":"2024"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.bja.2023.05.005","article-title":"Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss","volume":"131","author":"Weber","year":"2023","journal-title":"Br. J. Anaesth."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s11695-007-9203-2","article-title":"Foot drop as a complication of weight loss after bariatric surgery: is it preventable?","volume":"17","author":"Weyns","year":"2007","journal-title":"Obes. Surg."},{"key":"B66","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1507\/endocrj.EJ21-0129","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin","year":"2021","journal-title":"Endocr. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1608657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:29:42Z","timestamp":1751347782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1608657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":67,"alternative-id":["10.3389\/fphar.2025.1608657"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1608657","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"1608657"}}